0 32

Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Authors
 Jeong Eun Song  ;  Kyu Sik Jung  ;  Do Young Kim  ;  Kijun Song  ;  Jong Yun Won  ;  Hye Won Lee  ;  Beom Kyung Kim  ;  Seung Up Kim  ;  Jun Yong Park  ;  Sang Hoon Ahn  ;  Jinsil Seong  ;  Kwang-Hyub Han 
Citation
 International Journal of Radiation Oncology Biology Physics, Vol.99(2) : 396-406, 2017 
Journal Title
 International Journal of Radiation Oncology Biology Physics 
ISSN
 0360-3016 
Issue Date
2017
MeSH
Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy* ; Chemoembolization, Therapeutic/adverse effects ; Chemoembolization, Therapeutic/methods* ; Chemoembolization, Therapeutic/mortality ; Chemoradiotherapy/adverse effects ; Chemoradiotherapy/methods* ; Chemoradiotherapy/mortality ; Disease-Free Survival ; Female ; Fluorouracil/administration & dosage ; Humans ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Liver Neoplasms/therapy* ; Male ; Middle Aged ; Portal Vein ; Propensity Score ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Tumor Burden ; Venous Thrombosis ; Yttrium Radioisotopes/therapeutic use
Abstract
PURPOSE: It is unclear whether the efficacy and safety of concurrent chemoradiation therapy (CCRT) and transarterial radioembolization (TARE) with 90Y are comparable in patients with locally advanced hepatocellular carcinoma. METHODS AND MATERIALS: In total, 209 treatment-naive patients with stage B or C cancer according to the Barcelona Clinic Liver Cancer classification who were treated with TARE or CCRT were analyzed. Propensity scores were calculated and matched at a 1:1 ratio for TARE versus CCRT using age, tumor size, tumor number, portal vein thrombosis, and Barcelona Clinic Liver Cancer staging. In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy). Overall survival, freedom from progression, tumor response, and complication rate were compared between the TARE and CCRT groups. RESULTS: Among 209 patients, 124 (62 undergoing TARE and 62 undergoing CCRT) were selected after propensity score matching. Overall survival (TARE vs CCRT, 14.0 months vs 13.2 months, P=.435) and freedom from progression (6.9 months vs 7.8 months, P=.437) were comparable between the 2 groups. Objective response rates at 1 month after treatment were higher for CCRT than for TARE (46.8% vs 16.1%, P<.001), while objective response rates at 3 months were significantly higher for TARE than for CCRT (39.3% vs 21.4%, P=.04). There was no significant difference in long-term response rates (at 6 months and 1 year) between the 2 groups. The CCRT group experienced a higher rate of curative resection or liver transplantation after treatment than the TARE group, although the statistical significance was marginal (24.2% vs 11.3%, P=.060). Treatment-related complications were less frequent after TARE than after CCRT. CONCLUSIONS: Both treatments yielded comparable survival rates and long-term response rates in patients with intermediate- or advanced-stage hepatocellular carcinoma. The role of these modalities as a bridge to curative therapy requires further investigation.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/160860
Full Text
https://www.sciencedirect.com/science/article/pii/S0360301617309872
DOI
10.1016/j.ijrobp.2017.05.049
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실)
Yonsei Authors
김도영(Kim, Do Young)
김범경(Kim, Beom Kyung) ORCID logo https://orcid.org/0000-0002-5363-2496
김승업(Kim, Seung Up)
박준용(Park, Jun Yong) ORCID logo https://orcid.org/0000-0001-6324-2224
성진실(Seong, Jin Sil) ORCID logo https://orcid.org/0000-0003-1794-5951
안상훈(Ahn, Sang Hoon)
원종윤(Won, Jong Yun)
이혜원(Lee, Hye Won) ORCID logo https://orcid.org/0000-0002-3552-3560
정규식(Jung, Kyu Sik)
한광협(Han, Kwang Hyup)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse